Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 27 of the 41 sources its claims cite were checked for support.
Abstract
BACKGROUND: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III. METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks. There were two primary end points: the difference between the 80-mg olezarsen group and the placebo group in the percent change in the fasting triglyceride level from baseline to 6 months, and (to be assessed if the first was significant) the difference between the 50-mg olezarsen group and the placebo group. Secondary end points included the mean percent change from baseline in the apolipoprotein C-III level and an independently adjudicated episode of acute pancreatitis. RESULTS: A total of 66 patients underwent randomization; 22 were assigned to the 80-mg olezarsen group, 21 to the 50-mg olezarsen group, and 23 to the placebo group. At baseline, the mean (±SD) triglyceride level among the patients was 2630±1315 mg per deciliter, and 71% had a history of acute pancreatitis within the previous 10 years. Triglyceride levels at 6 months were significantly reduced with the 80-mg dose of olezarsen as compared with placebo (-43.5 percentage points; 95% confidence interval [CI], -69.1 to -17.9; P<0.001) but not with the 50-mg dose (-22.4 percentage points; 95% CI, -47.2 to 2.5; P = 0.08). The difference in the mean percent change in the apolipoprotein C-III level from baseline to 6 months in the 80-mg group as compared with the placebo group was -73.7 percentage points (95% CI, -94.6 to -52.8) and between the 50-mg group as compared with the placebo group was -65.5 percentage points (95% CI, -82.6 to -48.3). By 53 weeks, 11 episodes of acute pancreatitis had occurred in the placebo group, and 1 episode had occurred in each olezarsen group (rate ratio [pooled olezarsen groups vs. placebo], 0.12; 95% CI, 0.02 to 0.66). Adverse events of moderate severity that were considered by a trial investigator at the site to be related to the trial drug or placebo occurred in 4 patients in the 80-mg olezarsen group. CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, NCT04568434.).
Overview
CoChat Summary
TL;DR
In a phase 3 trial of patients with genetically identified familial chylomicronemia syndrome, olezarsen 80 mg every 4 weeks significantly reduced fasting triglycerides at 6 months versus placebo, while the 50-mg dose did not. Olezarsen also reduced apolipoprotein C-III and was associated with fewer adjudicated acute pancreatitis episodes over 53 weeks.
Key findings
- The 80-mg olezarsen group had a least-squares mean reduction in fasting triglycerides from baseline to 6 months of −43.5 percentage points versus placebo (95% CI, −69.1 to −17.9; P<0.001); the 50-mg dose did not meet significance (−22.4 percentage points; 95% CI, −47.2 to 2.5; P=0.08).
- Apolipoprotein C-III reductions from baseline to 6 months were −73.7 percentage points for 80 mg vs placebo (95% CI, −94.6 to −52.8) and −65.5 percentage points for 50 mg vs placebo (95% CI, −82.6 to −48.3).
- By 53 weeks, adjudicated acute pancreatitis occurred in 11 episodes in the placebo group and 1 episode in each olezarsen group (rate ratio for pooled olezarsen vs placebo, 0.12; 95% CI, 0.02 to 0.66).
- Adverse events of moderate severity considered related to trial drug or placebo occurred in 4 patients (18%) in the 80-mg olezarsen group.
Methods
- Phase 3, double-blind, placebo-controlled trial conducted from November 2020 through October 2023 at 29 centers in 11 countries; 66 patients with genetically identified familial chylomicronemia syndrome were randomized to olezarsen 80 mg (n=22), olezarsen 50 mg (n=21), or placebo (n=23) subcutaneously every 4 weeks for 49 weeks.
- Patients had fasting triglycerides ≥880 mg/dL and biallelic loss-of-function variants in LPL or related genes; baseline mean triglyceride level was 2630±1315 mg/dL, and 71% had a history of acute pancreatitis within the previous 10 years.
- Primary endpoints were hierarchical: difference between 80 mg and placebo in percent change in fasting triglycerides from baseline to 6 months, then the same for 50 mg vs placebo; secondary endpoints included apolipoprotein C-III change and independently adjudicated acute pancreatitis.
Limitations
- The paper states the trial cohort was small and there was uncertainty about adherence to dietary restrictions, which could have affected triglyceride lowering and acute pancreatitis incidence.
- The paper states the trial included mostly White patients, partly owing to genetic founder effects in European populations, and that larger, more diverse trials are needed.
- The paper notes that because the second primary endpoint was not significant, secondary endpoint results cannot be interpreted as definitive hypothesis tests and their confidence intervals were not adjusted for multiplicity; it also states postprandial fluctuations were not measured.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 3 Not valid · 7 Not checked · 64 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Olezarsen is an investigational GalNAc 3 -conjugated antisense oligonucleotide that reduces apolipoprotein C-III production by binding to APOC3 mRNA and inducing its degradation through ribonuclease H1-mediated cleavage of the sense strand. 26,28,29”
What the sources say
- Not checked — no full text of the sourcecites [26] 26. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab 2018; 27: 714-39. source
- Partly supportedcites [28] matched to “N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels” (2019) sourceExperimental — accuracy not yet measured
The Introduction describes AKCEA-APOCIII-LRx as a GalNAc3-modified antisense oligonucleotide targeting hepatic APOC3 mRNA, and the Discussion reports reduced plasma apoC-III. Our copy does not identify it by the name olezarsen or describe ribonuclease H1-mediated cleavage of the sense strand; those details are not supported by this source. (LLM, conf=0.86)
- Partly supportedcites [29] 29. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022; 43: 1401-12. 30. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. sourceExperimental — accuracy not yet measured
The Introduction (p. 4) identifies olezarsen as a GalNAc-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apoC-III production. Our copy does not specify that its conjugate is GalNAc3 or describe mRNA degradation through ribonuclease H1-mediated cleavage of the sense strand. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The condition is caused by biallelic loss-of-function variants in LPL (encoding lipoprotein lipase) or in related genes needed for LPL activity. 10-12”
What the sources say
- Supportedcites [10] 10. patients with familial chylomicronemia syndrome using FCS score-based data mining methods. J Clin Med 2022; 11: 4311. 10. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an 'FCS score.' Atherosclerosis 2018; 275: 265-72. source
The Introduction (p. 2) identifies homozygous or compound-heterozygous loss-of-function mutations in LPL and genes involved in LPL function as causes of FCS. Disease classification (p. 3) also lists homozygous loss-of-function mutations in related genes and compound-heterozygous mutations. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [11] matched to “Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association” (2020) source
- Supportedcites [12] 12. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 2017; 23: 1-7. source
Section 1.1 describes FCS as an autosomal recessive monogenic disease caused by mutations in genes encoding key molecules of the lipolytic cascade. Sections 1.2 and 3 identify LPL and four genes needed for its activity as causes when mutated and dysfunctional. The paper does not use the exact phrase “biallelic loss-of-function,” but its description supports that paraphrase. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Loss of LPL activity results in a reduced ability to hydrolyze triglycerides in triglyceride-rich lipoproteins, such as intestinally derived chylomicrons and hepatically derived very-low-density lipoproteins, leading to their accumulation in plasma and subsequent severe hypertriglyceridemia. 10-12”
What the sources say
- Partly supportedcites [10] 10. patients with familial chylomicronemia syndrome using FCS score-based data mining methods. J Clin Med 2022; 11: 4311. 10. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an 'FCS score.' Atherosclerosis 2018; 275: 265-72. sourceExperimental — accuracy not yet measured
The Introduction (p. 2) says LPL hydrolyses triglycerides and that loss of LPL function impairs clearance of intestinally derived chylomicrons. Disease classification (p. 3) links LPL deficiency in FCS with severe, persistent hypertriglyceridemia. Our copy does not establish the citing sentence’s additional point about hepatically derived VLDL accumulating through this mechanism. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [11] matched to “Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association” (2020) source
- Supportedcites [12] 12. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 2017; 23: 1-7. source
Section 1.2 states that LPL hydrolyzes triglycerides in chylomicrons and VLDL. Section 3 links impaired lipolysis of triglyceride-rich lipoproteins to chylomicronemia, and Section 2 reports severe hypertriglyceridemia in patients with LPL deficiency. Together, these passages support the attributed causal chain. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“and these agents have not been effective in lowering triglyceride levels in patients with familial chylomicronemia syndrome. 21,34”
What the sources say
- Not checked — no full text of the sourcecites [21] 21. Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all? Eur Heart J 2022; 43: 1413-5. source
- Could not verifycites [34] 34. Borén J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne) 2020; 11: 474. sourceExperimental — accuracy not yet measured
The Pharmacological Interventions section says fibrates have variable effects on APOC3 expression and omega-3 fatty acids moderately reduce apoC-III levels. It reports triglyceride lowering in familial chylomicronemia syndrome with volanesorsen, but does not address whether fibrates or omega-3 fatty acids fail to lower triglycerides in those patients (searched for familial chylomicronemia and conventional treatments). (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III.”
What the sources say
- Not checked — no full text of the sourcecites [26] 26. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab 2018; 27: 714-39. source
- Supportedcites [28] matched to “N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels” (2019) source
The Discussion reports that AKCEA-APOCIII-LRx targets APOC3 mRNA and significantly lowers plasma apoC-III and triglycerides in subjects with hypertriglyceridaemia. The paper describes the drug as hepatocyte-targeted and as inhibiting apoC-III protein synthesis. It uses the developmental name AKCEA-APOCIII-LRx rather than olezarsen. (LLM, conf=0.87)
- Supportedcites [29] 29. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022; 43: 1401-12. 30. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24. source
The Introduction (p. 4) states that olezarsen targets hepatic APOC3 mRNA to inhibit apoC-III protein production. The Methods and results (p. 2) report significant reductions in fasting triglyceride levels with olezarsen compared with placebo. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
36 more claims · 4 with their cited sources checked
Create a free account to see all 89 claims and every source verdict.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 33
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“LDL Cholesterol(LDL-C) increased significantly in the olezarsen group at 6 months (MD = 52.75%;95% CI: 42.17, 63.33; P=.00001;I 2 = 31%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“and at 12 months (MD = -22.90%;95% CI: -26.47, -19.32;P=.0001;I 2 = 0%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Sensitivity analyses excluding patients with familial chylomicronemia syndrome demonstrated that statistically significant reductions in the mean percentage change from baseline in TG and apolipoprotein C-III levels persisted, although substantial heterogeneity remained”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Subgroup analyses evaluating dose-dependent effects showed significant reductions in TG levels at both the 50-mg dose (MD = -50.81;95% CI: -63.28, -38.34;P = .0001;I² = 64%)”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Sensitivity analyses excluding patients with familial chylomicronemia syndrome demonstrated that statistically significant reductions in the mean percentage change from baseline in TG and apolipoprotein C-III levels persisted, although substantial heterogeneity remained”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Self-citationHegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citation
Research works printed but not linked: 1
- 11. United States adults. Am J Cardiol 2011; 107: 891-7.
Cited by
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409368 · Cited by 215
Self-citationOlezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402309 · Cited by 214
Self-citation2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120479 · Cited by 159
Párniczky, A., Mikó, A., Uç, A., Singh, A. N., Elhence, A., Saluja, A., Masamune, A., Dayyeh, B. K. A., Davidson, B. R., Wilcox, C. M., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.04.020 · Cited by 233
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2507227 · Cited by 78
Self-citationFamilial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.03.013 · Cited by 60
Self-citationTarget Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Gene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 51
2024 FDA TIDES (Peptides and Oligonucleotides) Harvest
Musaimi, O. A., Shaer, D. A., de la Torre, B. G., & Alberício, F. (2025) · Pharmaceuticals · doi:10.3390/ph18030291 · Cited by 51
“Moderate adverse events were reported in 18% of patients receiving 80 mg olezarsen [33].”
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Topouzis, S., Papapetropoulos, A., Alexander, S. P. H., Cortese-Krott, M. M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A., Patel, H. H., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17458 · Cited by 43
Spagnuolo, C. M., Wang, J., McIntyre, A. D., Kennedy, B. A., & Hegele, R. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae613 · Cited by 42
Self-citationAdvances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 35
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Kovanen, P. T., Lloyd‐Jones, D. M., Raal, F. J., Santos, R. D., & Watts, G. F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02089-0 · Cited by 30
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32
“The phase 3 Balance trial included 66 patients with genetically confirmed FCS [70].”
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies
Ray, K. K., Linnebjerg, H., Michael, L. F., Shen, X. P., Ma, X., Lim, S., Zhen, Y., Dudek, H., Abrams, M., Saxena, U. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.005 · Cited by 32
Syed, Y. Y. (2025) · Drugs · doi:10.1007/s40265-025-02166-0 · Cited by 29
“The efficacy of olezarsen in treating FCS was demonstrated in the randomized, double-blind, placebo-controlled phase 3 Balance (NCT04568434) trial [14].”
InfluentialTramontano, D., D'Erasmo, L., Larouche, M., Brisson, D., Lauzière, A., Di Costanzo, A., Bini, S., Minicocci, I., Covino, S., Baratta, F., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119146 · Cited by 23
Self-citationMolecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
Syed‐Abdul, M. M., Tian, L., Hegele, R. A., & Lewis, G. F. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00028-2 · Cited by 27
Self-citationBallantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
Self-citationGurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Pan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 22
Self-citationKamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Mondal, S., Bhattacharya, S., & Kalra, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.013 · Cited by 18
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
“Four of these studies investigated the effects of volanesorsen [18, 25, 26, 38], three examined the impact of Plozasiran [19, 37, 40], and the remaining three studied olezarsen [20, 39–41].”
Patel, S. B., Belalcazar, L. M., Afreen, S., Balderas, R., Hegele, R. A., Karpe, F., Ponte-Negretti, C. I., & Rajpal, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.014 · Cited by 23
Self-citationEtiology and emerging treatments for familial chylomicronemia syndrome
Spagnuolo, C. M., & Hegele, R. A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365787 · Cited by 20
“Incident pancreatitis events were markedly reduced by 88% in patients who received olezarsen [26].”
BackgroundSelf-citationKarwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hoenlinger, A., Margolskee, A., Li, L., & Tsimikas, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02297-5 · Cited by 19
“The Balance (NCT04568434) trial for FCS enrolled 66 patients and recent data revealed significant reductions in triglycerides with the 80 mg olezarsen dose, and marked reductions in pancreatitis events [16].”
BackgroundMethodInfluentialSelf-citationResidual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 31
Self-citationAn overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Self-citationSaadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.012 · Cited by 30
“For instance, the TG level in genetically confirmed FCS patients in the Balance trial ranged from 334 to 6898 mg/dL. 60 Therefore, the appropriate cut point for defining PC is unclear.”
Self-citationSaadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100978 · Cited by 22
“…(cid:0) 69 to (cid:0) 18; P < 0.001) in the 80-mg monthly arm and (cid:0) 22 % ( (cid:0) 47 to 3; P = 0.08, not statistically significant) in the 50-mg monthly arm, and reduced the risk of pancreatitis (a secondary endpoint) by 88 % (rate ratio 0.12; 95 % confidence interval 0.02 to 0.66) [60].”
InfluentialSelf-citationSamson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
de Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 16
Bergmark, B. A., Marston, N., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Murphy, S. A., Zhang, S. M., Lu, M. T., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.022 · Cited by 17
Self-citationNovel RNA-Based Therapies in the Management of Dyslipidemias
Kosmas, C. E., Bousvarou, M. D., Tsamoulis, D., Gianniou, M., Papakonstantinou, E. J., & Rallidis, L. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031026 · Cited by 20
“Four patients in the 80 mg olezarsen group experienced adverse reactions of moderate severity [47].”
Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia
Bashir, B., Ferdousi, M., Durrington, P. N., & Soran, H. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000939 · Cited by 14
Self-citationOlezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408369 · Cited by 17
“In the BALANCE phase III double-blind placebo controlled trial, patients with genetically confirmed FCS were assigned to receive 50 mg ( n = 21) or 80 mg ( n = 22) olezarsen or placebo ( n = 23) every 4 weeks for 53 weeks [29]; NCT04568434.”
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Progress in RNA‐Targeted Therapeutics for Human Diseases
Zhang, W., Jiang, A., Jia, B., Jin, Y., Chen, Y., Li, Z., Liao, Y., Zhang, H., Lin, Z., Fang, X., et al. (2026) · MedComm · doi:10.1002/mco2.70607 · Cited by 22
Marston, N. A., Bergmark, B. A., Alexander, V. J., Karwatowska‐Prokopczuk, E., Kang, Y. M., Moura, F. A., Prohaska, T. A., Zimerman, A., Zhang, S. M., Murphy, S. A., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.03.003 · Cited by 13
Self-citationNovel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
“The phase 3 BALANCE trial (NCT04568434) randomized genetically confirmed FCS patients to receive either 80 mg or 50 mg of olezarsen, or a placebo, every four weeks for 49 weeks [46].”
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
“In these patients, baseline LDL-C is often artificially low due to defective VLDL remodeling [32, 33, 35, 45, 46 ].”
InfluentialSelf-citationMasson, W., Lobo, M., Nogueira, J. P., Corral, P., Barbagelata, L., & Siniawski, D. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09893-x · Cited by 12
“Additionally, one study enrolled patients with severe hypertriglyceridemia, some of whom were diagnosed with FCS [12], while another two studies exclusively recruited patients with this condition [11, 17].”
InfluentialTsimikas, S., Ginsberg, H. N., Alexander, V. J., Karwatowska‐Prokopczuk, E., Dibble, A., Li, L., Witztum, J. L., & Hegele, R. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.018 · Cited by 12
Self-citationBarbour, S. J., Hladunewich, M., McCaleb, M. L., Robson, R. A., Barrett, T. D., Yin, L., Frazer‐Abel, A. A., Jp, G., Geary, R. S., Schneider, E., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.11.017 · Cited by 16
Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications
Zubirán, R., Cruz‐Bautista, I., & Aguilar-Salinas, C. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01626-2 · Cited by 13
“Similarly, recently published results from the BALANCE study where at 6 months of treat‑ ment, TG levels were significantly reduced with olezarsen 80 mg (− 43.5%; 95% CI − 69.1 to − 17.9; p < 0.001) [118], but not with olezarsen 50 mg (− 22.4%; 95% CI − 47.2 to 2.5; p = 0.08).”
BackgroundResultInfluentialRosenson, R. S., George, R. T., Sanchez, R. J., Zhao, X.-Q., Ponda, M. P., Waldron, A., & Pordy, R. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.07.005 · Cited by 11
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 15
“This model revealed a direct correlation between ApoC3 and atherogenesis [159].”
Maidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 14
“These data support the hypothesis that pharmacologic lowering of TRLs via APOC3 inhibition should 66 patients with FCS and fasting TG > 880 mg/dL ( > 10 mmol/L) received either olezarsen 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks [47].”
InfluentialSelf-citationChronic and Idiopathic Pancreatitis—A Personalized Treatment Approach
von Widdern, J. C., Rosendahl, J., & Ammer‐Herrmenau, C. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12741 · Cited by 11
“Two antisense oligonucleotide drugs, Olezarsen and Vola-nesoren, have proven efficiency in placebo controlled trials, decreasing both triglyceride plasma levels and the rate of pancreatitis episodes [27, 28].”
Saadatagah, S., Naderian, M., Larouche, M., Gaudet, D., Kullo, I. J., & Ballantyne, C. M. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.008 · Cited by 12
Self-citationKraaijenhof, J. M., Peletier, M. C., Nurmohamed, N. S., Hovingh, G. K., Alexander, V. J., Tsimikas, S., Stroes, E. S. G., & Kroon, J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf478 · Cited by 10
Self-citationAtherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 14
Kalwick, M., & Roth, M. M. (2025) · Nutrients · doi:10.3390/nu17040659 · Cited by 21
“The APOC3 antisense oligonucleotide, olezarsen, was approved for the treatment of FCS on top of diet therapy [136].”
Olezarsen for the Treatment of Familial Chylomicronemia Syndrome
Phillips, B., Abbott, C., Breit, S., & Onge, E. S. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251332500 · Cited by 10
“17 However, it is important to note that the clinical trials for olezarsen took place during the COVID-19 pandemic.”
D’Erasmo, L., Tramontano, D., Di Costanzo, A., Casula, M., Galimberti, F., Baratta, F., Cefalù, A. B., Tarugi, P. M., Calandra, S., Zambon, A., et al. (2025) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.125.323340 · Cited by 9
Self-citationA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
Aksoyalp, Z. Ş., Kayki‐Mutlu, G., Wojnowski, L., & Michel, M. C. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04020-2 · Cited by 11
“Olezarsen is an antisense oligonucleotide designed to target messenger RNA of apolipoprotein C-III and is used as an adjunct to diet.”
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
The RNA revolution in medicine: from gene regulation to clinical therapeutics
Jeong, J., & Jeong-Yu, S. (2025) · Animal Cells and Systems · doi:10.1080/19768354.2025.2548253 · Cited by 12
“Clinical studies have demonstrated that olezarsen effectively lowers APOC3 levels and serum triglycerides, particularly in patients with cardiovascular disease or at high risk of it (Stroes et al. (2024)).”
RNA-based therapeutic opportunities for the treatment of kidney diseases
Prins, J., Biscans, A., van Zonneveld, A. J., Frazier, K. S., & van der Veer, E. P. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01011-7 · Cited by 13
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review
Subramanian, S., Soran, H., Kessler, A. S., McClain, M. R., Eckel, R. H., & Rosenson, R. S. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106648 · Cited by 13
Self-citationApproach to the Adult Patient with Chylomicronemia
Hegele, R. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf701 · Cited by 14
Self-citationRNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management
Mohammadi, A., Karimian, A., Shokri, K., Mohammadi, A., Karzar, N. H., Bahar, R., Radfar, A., Pakyari, M., & Tehrani, B. N. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10603-4 · Cited by 8
“ARO-APOC3 (plozasiran) is another therapeutic siRNA that inhibits apoC-III [23, 24].”
Yang, X., Alexander, V. J., Xia, S., & Tsimikas, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120462 · Cited by 7
Self-citationKessler, A. S., Baum, S. J., Kutrieb, E., Vera‐Llonch, M., Lonshteyn, A., Weycker, D. A., & Soffer, D. E. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02658-8 · Cited by 9
“…the risks of AP and CV indirectly by treating the secondary cause is a matter that has not been fully established, although recent evidence from randomized clinical trials has shown that TG reduction lowers AP risk in patients with primary HTG (e.g., familial chylomi-cronemia syndrome) [11, 12].”
Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia
Prakash, T. P., Mullick, A. E., Riney, S., Yu, J., Nikan, M., Quirk, C., Crutchfield, A., Damle, S. S., Klein, S., & Swayze, E. E. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1063 · Cited by 8
“…therapies such as olezarsen (TRYNGOLZA™), which recently gained FDA approval to reduce plasma triglycerides (TG) along with diet in adults with familial chylomicronemia syndrome (FCS) [ 31 ]. siRNA inhibitors of APOC3 expression have demonstrated similar effects on triglyceride lowering.”
Tian, Z., Luo, H., Chu, Y., Liu, Y., Gao, S., Song, L., Yang, Z., & Liu, D. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01513-4 · Cited by 6
“RNAi-based therapeutics for APOC3 gene silencing are currently approved or in clinical trials [18], including the ASO drug volanesorsen [19], the GalNAc-conjugated ASO drug olezarsen [20], and the GalNAc–siRNA drug plozasiran [21].”
Saddique, M. N., Thapa, R., Khan, Y., Javaid, H., Khawar, M. M., Rehman, A., Dave, R., Raval, R., Hejmadi, S., Singh, P., et al. (2025) · Discover Medicine · doi:10.1007/s44337-025-00329-2 · Cited by 6
“Conventional therapies such as fibrates and omega-3 fatty acids have been ineffective in lowering TG levels in FCS patients, Olezarsen has shown promising results [16, 19].”
Ashraf, T., Devi, N., Aradhna, F., Devi, S., Nancy, F., Kumar, A., Ameer, F., Absar, F., Kumar, L., Kumar, S., et al. (2025) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000003505 · Cited by 6
RNA‐Based Therapeutics: Cutting‐Edge Advances in Clinical Research
Ferreira, D., & Rodrigues, L. R. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500082 · Cited by 7
Brown, A. S., Moulin, P., Dibble, A., Alexander, V. J., Li, L., Gaudet, D., Witztum, J. L., Tsimikas, S., & Hegele, R. A. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.008 · Cited by 7
Self-citationLi, D., Liu, Z., & Jiang, H. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02862-0 · Cited by 11
“Renal safety profiles were comparable between the olezarsen and placebo groups [66].”
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8
Self-citationGenetic determinants of pancreatitis risk in hypertriglyceridemia
Paquette, M., Guay, S., & Baass, A. W. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000962 · Cited by 6
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
“In the phase 3 Balance trial (NCT04568434) in patients with FCS, olezarsen 80 mg or 50 mg or placebo was given SC every 4 weeks for 49 weeks [53].”
Emerging agents targeting triglycerides
Prakash, Y. S., Bhatt, D. L., & Malick, W. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000979 · Cited by 7
Programmable Single-Stranded Circular Antisense Oligonucleotides for Multitarget Gene Therapy
Pan, Y., Li, X., Zhu, C., Wang, M., Wu, Y., Xu, R. D., Wu, J., Chen, R.-T., Jiang, Y., Tian, B., et al. (2025) · JACS Au · doi:10.1021/jacsau.5c00584 · Cited by 9
Shooting the Messenger to Treat Hypertriglyceridemia
Watts, G. F. (2024) · New England Journal of Medicine · doi:10.1056/nejme2402653 · Cited by 9
Maidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 8
“In BALANCE, which was conducted with a similar patient population as PALISADE, the baseline mean TG level was 2,630 mg/dL, and patients who received the highest dose of olezarsen had a median reduction of – 34% (IQR – 54 to – 9], like-wise leaving many patients above TG goal of 500 mg/dL [16].”
InfluentialAdvancements in research to mitigate residual risk of atherosclerotic cardiovascular disease
Shi, F., Dou, J., & Zhang, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-03006-3 · Cited by 13
“In phase 3, double-blind, placebo-controlled trial, olezarsen could significantly reduce plasma triglyceride levels in patients with familial chylomicronemia syndrome [73].”
Reijnders, E., Bossuyt, P. M., Jukema, J. W., Ruhaak, L. R., Romijn, F. P. H. T. M., Szarek, M. J., Trompet, S., Bhatt, D. L., Bittner, V., Díaz, R., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322336 · Cited by 7
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 11
Ray, K. K., & Kronenberg, F. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120636 · Cited by 6
Toth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 9
“…(BALANCE), 66 patients with genetically confirmed FCS (homozygous or heterozygous compound loss function mutations in the genes for LPL, apoC2, apoA5, LMF-1 , or GPIHBP1 ) and fasting TG ≥ 880 mg/dl ( ≥ 10 mmol/l) were randomized to receive placebo or olezarsen at 50 or 80 mg monthly [106].”
InfluentialFogacci, F., & Cicero, A. F. G. (2026) · Diseases · doi:10.3390/diseases14020047 · Cited by 9
“Newer agents aim to improve the efficacy–tolerability balance: in a phase 2b trial, olezarsen lowered triglycerides by 43.5% at 6 months (vs. 6.2% with placebo), and pancreatitis episodes were less frequent (11 with placebo vs. 1 in each active-dose group) [33].”
InfluentialExome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity
Kim, H. I., DeBoever, C., Walter, K., Kalantzis, G., Li, C., Mozaffari, S. V., Kundu, K., Jacobs, B. M., Mohammadi‐Shemirani, P., Musolf, A. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02553-7 · Cited by 12
Weijs, B. M., Oostveen, R. F., Kraaijenhof, J. M., & Stroes, E. S. G. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000906 · Cited by 5
“During the 12-month follow-up period, one acute pancreatitis event was recorded among 21 patients using 50 mg ole-zarsen, 1 event among 22 patients using 80 mg versus 11 events (in seven patients) among 23 patients using placebo [13 & ].”
InfluentialSelf-citationBroder, M. S., Chang, E. Y., Villa, K. F., & Wong, N. D. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.017 · Cited by 5
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 9
“…lipase and metabolism of TRLs. Early studies have demonstrated that ANGPTL3 inhibition produces dose dependent lowering of triglycerides, particularly in the setting of familial chylomicronemia syndrome [91,92], and LDL cholesterol in patients with homozygous familial hypercholesterolemia [93].”
BackgroundInfluentialApolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen
Valdivielso, P., & Coca Prieto, I. (2024) · Med · doi:10.1016/j.medj.2024.05.004 · Cited by 5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Mansoor, T., Nambi, V., Parikh, S. S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L. S., Virani, S. S., Rifai, M. A., Koshy, S. K. G., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00748-7 · Cited by 4
“…study, NCT04568434 “a study of olezarsen (formerly known as AKCEA-APOCIII-LRx) administered to patients with familial chylomicronemia syndrome” (BAL-ANCE) published in 2024, investigated the effect of 50 mg and 80 mg of olezarsan compared with placebo in 66 patients with FCS [46].”
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
Nucleic Acid–Based Therapies — The Next Frontier in Treating Dyslipidemias
Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.026 · Cited by 5
Self-citationGao, Y., Bai, Y., Mu, X., & Pang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736821 · Cited by 4
“Ultimately, eight studies met the inclusion criteria and were included in the meta-analysis (Gaudet et al., 2024; Ray et al., 2025; Tardif et al., 2022; Bergmark et al., 2024; Stroes et al., 2024; Ballantyne et al., 2024; Rosenson et al., 2024; Bergmark et al., 2025).”
Influential
Metadata
- Authors
- Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., Witztum, J. L., & Tsimikas, S.
- Affiliations
- Western University (CA)
- From the Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, (E.S.G.S.); Ionis Pharmaceuticals, Carlsbad (V.J.A., E.K.-P., T.A.P., S.X., S.T.), and the Divisions of Endocrinology and Metabolism (J.L.W.) and Cardiovascular Medicine (S.T.), Department of Medicine, University of California, San Diego, La Jolla — both in California; the Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (R.A.H.); the Department of Translational and Precision Medicine, Center for Rare Disorders of Lipid Metabolism, Sapienza University of Rome, Rome (M.A.); Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); the National Institute for Health Research and Wellcome Trust Clinical Research Facility, Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom (H.S.); and the Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York (H.N.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-16
- Volume
- 390
- Issue
- 19
- Pages
- 1781-1792
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4394062061
- Cited by
- 271
- References
- 37
- Citations by year
- 2026: 115 · 2025: 112 · 2024: 44
- FWCI
- 81.10
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- olezarsen, familial chylomicronemia syndrome, acute pancreatitis, hypertriglyceridemia, apolipoprotein C-III, antisense therapy, triglyceride lowering, hepatic triglyceride synthesis, dose comparison, drug safety and efficacy, adverse events, serious adverse events
- MeSH terms
- Acute Disease, Adult, Aged, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Pancreatitis, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


